Acute generalized exanthematous pustulosis due to ceftriaxone: Report of a pediatric case with recurrence after positive patch test

2019 ◽  
Author(s):  
Andac Salman ◽  
Deniz Yucelten ◽  
Ozlem Akin Cakici ◽  
Eda Kepenekli Kadayifci
Keyword(s):  
Patch Test ◽  
Pediatric Case ◽  
Positive Patch Test ◽  
Acute Generalized Exanthematous Pustulosis ◽  
Exanthematous Pustulosis

Terbinafine-induced acute generalized exanthematous pustulosis confirmed by a positive patch-test result

1997 ◽  
Vol 37 (4) ◽  
pp. 653-655 ◽  
Author(s):  
Anne Kempinaire ◽  
Linda De Raevea ◽  
Myriam Merckx ◽  
Arlette De Coninck ◽  
Martine Bauwens ◽  
...  
Keyword(s):  
Patch Test ◽  
Positive Patch Test ◽  
Acute Generalized Exanthematous Pustulosis ◽  
Exanthematous Pustulosis ◽  
Test Result

scholarly journals Acute Generalized Exanthematous Pustulosis due to Pseudoephedrine with Positive Patch Test

2006 ◽  
Vol 86 (6) ◽  
pp. 542-543 ◽  
Author(s):  
E Mayo-Pampín ◽  
? Flórez ◽  
C Feal ◽  
A Conde ◽  
MT Abalde ◽  
...  
Keyword(s):  
Patch Test ◽  
Positive Patch Test ◽  
Acute Generalized Exanthematous Pustulosis ◽  
Exanthematous Pustulosis

scholarly journals Mucosal Fixed Drug Eruption to Levetiracetam with Early Positive Patch Test on Non-Lesional Skin

2021 ◽  
Author(s):  
Nazli Ercan
Keyword(s):  
Patch Test ◽  
Broad Spectrum ◽  
Drug Eruption ◽  
Hepatic Metabolism ◽  
Fixed Drug Eruption ◽  
Pediatric Case ◽  
Lesional Skin ◽  
Positive Patch Test ◽  
Low Protein ◽  
Fixed Drug

Levetiracetam (LEV) is a second-generation antiepileptic drug (AED) that is well tolerated, has a broad spectrum of action, low protein binding, and minimal hepatic metabolism. The incidence of hypersensitivity to LEV in children and adults is 0.6%. This is the first reported fixed drug eruption (FDE) identified using a patch test in a pediatric case associated with LEV

Sign in / Sign up

Export Citation Format

Share Document